seasonal influenza vaccination & pneumococcal vaccination ......(+2 024.0%) children aged...
TRANSCRIPT
Seasonal Influenza Vaccination
& Pneumococcal Vaccination Arrangement for 2019/20
1
Vaccination Programmes/Schemes
1. Government Vaccination Programme (GVP)
2. Vaccination Subsidy Scheme (VSS)
3. School Outreach (For Seasonal Influenza
Vaccination only)
2
Seasonal Influenza Vaccination
(SIV)
3
SI Vaccines in 2018/19 had expired on
31 August 2019
Number of doses given
• Government Vaccination Programme (GVP) 492 000
• Vaccination Subsidy Schemes (VSS) 583 000
• School Outreach Vaccination Pilot Programme 121 000
Increased by
46%as compared
with 17/18
Total:
> 1 196 000
4
• Majority of institutional outbreaks of ILI was
recorded in schools including primary
schools and kindergartens/child care centres
(KGs/CCCs)
• High influenza-associated hospital admission
rates among children
School Outreach Programme
Aims to increase seasonal influenza vaccination uptake
amongst school children and prevent influenza-related
hospital admissions and complications
Why School Outreach Pilot
5
School Outreach 2018/19
6
SIV Statistics 2018/19 by target groups
7
Category
GVP
(including
RVP)
VSS
School
Outreach
Pilot
2018/19
Total no. of
doses administered
Comparison
between
2017/18 and
2018/19
Elderly aged 65 years or
above 388 000 167 000
N/A555 000
+23 600
doses
(+4.4%)
Persons aged 50 to 64 7 150 150 000N/A
157 000
+ 150 000
doses
(+2 024.0%)
Children
aged between 6
months to less
than 6 years
1 140 145 000N/A
146 000
+34 000
doses
(+30.5%)
aged between 6
years to less than
12 years
120 115 000 121 000 237 000
+160 000
doses
(+205.1%)
Total for Children 1 260 260 000 121 000 383 000
+193 000
doses
(+102.1%)
Healthcare workers 54 900 N/A N/A 54 900+9 000 doses
(+19.7%)7
School typeWithout outreach
vaccination
With outreach
vaccination
KGs/CCCs
(n=1,063)
394 / 879
(44.8%)
51 / 184*
(27.7%)
Primary schools
(n=587)
66 / 184
(35.9%)
76 / 403*
(18.9%)
Proportion of schools with ILI
outbreaks in 2018/19 winter influenza
season
38%
47%
* Note: Schools having outbreaks within 2 weeks after outreach vaccination are not
counted (1 KG/CCC & 1 primary school). One primary school with outreach SIV for
staff only was also not counted.
SIV Programmes in 2019/20
9
SCVPD Recommendations on SIV for
2019/20 Same priority groups as
recommended in the 2018/19
SIV composition
Both inactivated and live attenuated
vaccine are recommended
Take reference from
evaluation of 2018/19
Programme
10
Recommendations on SIV composition
for 2019/20 (northern hemisphere)
• Quadrivalent vaccine contains the following:
an A/ Brisbane/ 02/ 2018 (H1N1) pdm09-like virus
an A/ Kansas/ 14/ 2017 (H3N2)-like virus
a B/ Colorado/ 06/ 2017-like virus
a B/ Phuket/ 3073/ 2013-like virus
• Both inactivated influenza vaccine (IIV) and live attenuated influenza
vaccine (LAIV) are recommended for use in Hong Kong
• For IIVs, quadrivalent is preferred to trivalent due to additional
protection against one more lineage of influenza B
11
SIV Programmes in 2019/20
• School Outreach
• GVP (including
Residential Care Home
Vaccination Programme
RVP)
• VSS
Key New Initiatives
To step up SIV via
School Outreach
To enhance
workflow & increase
amount of subsidy
for School Outreach
& RVP
To cover residential
child care centres in
RVP
12
GVP
• Free vaccination to eligible groups
at HA and DH premises
at institutions under RVP
Eligible groups &
arrangement unchanged
Enhanced workflow;
Subsidy $100 per dose
13
Eligible groups of GVP 2019/20
14
Eligible groups of GVP 2019/20
* Must be Hong Kong residents
** Certificate for Waiver of Medical Charges issued by Social Welfare Department
15
Eligible groups of VSS
• Subsidized
vaccination to
eligible groups by
private doctors
1616
VSS
• Private doctors (VSS doctors) may or may not
charge extra fee
• For VSS doctors information, please visit
eHeath system (subsidies)
17
High-risk conditions (under GVP/VSS)
(Criteria: Remain the same)High-risk conditions include both risk factors for
seasonal influenza and invasive pneumococcal diseases
History of invasive pneumococcal disease, cerebrospinal fluid leakage or
cochlear implant;
Chronic cardiovascular (except hypertension without complications), lung,
liver or kidney diseases;
Metabolic diseases including diabetes mellitus or obesity (Body Mass Index
30 or above);
Immunocompromised states related to weakened immune system due to
conditions such as asplenia, Human Immunodeficiency Virus
infection/Acquired Immune Deficiency Syndrome or cancer/steroid treatment;
Chronic neurological conditions that can compromise respiratory functions or
the handling of respiratory secretions, or increase the risk of aspiration, or
those who lack the ability to take care of themselves
Children and adolescents (aged 6 months to 18 years) on long-term therapy.
18
School Outreach
• Service providers: Public-private-partnership (PPP)
vaccination teams & DH teams
• Free vaccination
• Cover more schools
Primary schools
Kindergartens (KG), Kingdergartens-cum-child-care-
centres, Child-care-centres (CCC) – pilot this year
• Cover more students
All students in participating schools, irrespective of HK
resident status, can receive free vaccination19
Primary School
Outreach
Kindergarten / Child
Care Centre Outreach
(Pilot)
Quota No quota
Eligibility All students, regardless of Hong Kong
resident status
Charge Free*
VSS Outreach (if for schools) can allow extra charge
20
Primary School
Outreach
Kindergarten / Child
Care Centre Outreach
(Pilot)
Provision of
vaccination
Mainly public-private-partnership (PPP)
outreach team
Vaccine procurement
& deliveryGovernment PPP doctors
Subsidy to PPP
doctors
HKD$100 for each
dose
HKD$260 for each
dose
21
Enrollment of School Outreach
• The Department of Health (DH) has held
briefings for stakeholders:
• In February & March 2019 for private doctors and
schools to invite them to enroll in the programme
• In June 2019 to private doctors and schools on the
preparatory arrangement and operational details
for outreach activities
• As at 1 September 2019, approximately
430 primary schools and 700 KG/CCC
have enrolled
22
Types of SIVs used under GVP, VSS,
and School Outreach
• Inactivated influenza vaccine (IIV)
• Available in quadrivalent (QIV) and trivalent (TIV) forms
• QIV is preferred to TIV due to the additional protection against
one more lineage of influenza B
• Administered through injection
• Can be used for persons aged 6 months and above
• Live attenuated influenza vaccine (LAIV)
• Administered intranasally
• Indicated for 2-49 years of age, except: those who are pregnant,
immunocompromised, or with other contraindications
(Please refer to the drug inserts for details before vaccination)
23
Types of SIVs used under GVP, VSS,
and School OutreachProgramme(s) Type of vaccines
• GVP IIV (quadrivalent) only
• VSS
• School Outreach (Free of
charge) – KG/CCC (pilot)
Doctors can choose to use IIV or
LAIV (quadrivalent)* as indicated
• School Outreach (Free of
charge) – Primary School
Outreach
IIV (quadrivalent) for most schools
(DH will test use LAIV in school
outreach to test the feasibility and
logistics arrangement.)
24
*According to vaccine supplier – limited supply of LAIV to Hong Kong for 2019/20
Reinforce Public Education
25
Reasons for receiving / not receiving SIV
(General Public)
Reasons for receiving
• 32.8% believed that vaccination is
effective in reducing the risk of
flu/ease flu-like symptoms
• 21.3% worry of getting flu/peak flu
season
• 17.5% recommended by health
care workers
• 16.6% have a habit to receive the
vaccination every year
• 13.5% know there is free /
subsidised vaccination
Reasons for not receiving
• 45.9% perceive themselves as
being healthy and will not easily
get the flu
• 14.1% are concerned about
effectiveness of SIV
• 10.4% are concerned about the
safety of SIV
• 9.7% consider vaccine is
expensive
• 8.5% have no time
Source: Seasonal influenza vaccination coverage survey for the 2015/16 season. Reported on
Communicable Disease Watch. Dec 18 – Dec 31, 2016
26
Role of HCWs in promoting SIV
Promote SIV to patients
• Be proactive in promoting, especially to persons in the priority
groups
• Clarify main concerns about effectiveness and safety of the
vaccination
Get vaccination themselves
• Reduce morbidity related to respiratory infections
• Reduce risk of transmitting influenza to patients who are at
high-risk of complications and mortality
• Strengthen capacity during peak season
27
• Work closely with health care
sectors, community partners and
education sectors to promote
vaccination
• Publicise through a series of media
activities and various channels
TV and radio (New API)
Websites / Facebook
Briefing session
Specialist interviews
Videos
Articles to newspapers and magazines
Leaflets and posters
Advertisements
Health education hotline
Public education and risk communication
28
Pneumococcal Vaccination
(PV) for the Elderly
29
PV Programmes in 2019/20
• Continue the same arrangement as 2018/19
Elderly aged 65
years or above
Have never received
pneumococcal
vaccination
Have received 23vPPV
With high-risk
conditions
One dose of free or
subsidised PCV 13
followed by one dose
of 23vPPV one year
after
One dose of free or subsidised
PCV13 mop-up vaccination
one year after the previous
dose of 23vPPV
Without high-
risk conditions
Continue to provide
one dose of free or
subsidized 23vPPV
No need to re-vaccinate
30
PV Programmes in 2019/20
• No change in eligibility under GVP and VSS
• VSS subsidy levels remain the same
• 23vPPV: HKD$250 per dose
• PCV13: HKD$730 per dose
31
Will start on 9 Oct 2019
Vaccination Subsidy
Scheme
2019/20 SIV School
Outreach (Free of charge)
– KG/CCC (pilot)
Vaccination Programmes Start Dates
Will start on 23 Oct 2019
Government Vaccination
Programme
2019/20 SIV School
Outreach (Free of charge)
– Primary School Outreach
32
Conclusion
1. Lessons learnt from 2018/19 Programmes
2. To plan, enhance and implement 2019/20
Programmes
3. Collaboration
33
Thank You
Please visit the following website for more
details:
https://www.chp.gov.hk/en/features/17980.html
Vaccination Office Enquiry Number :
2125 2125
34